Concurrent Investment Advisors LLC Has $4.87 Million Holdings in Pfizer Inc. $PFE

Concurrent Investment Advisors LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 11.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 200,775 shares of the biopharmaceutical company’s stock after purchasing an additional 20,663 shares during the period. Concurrent Investment Advisors LLC’s holdings in Pfizer were worth $4,867,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the 1st quarter worth about $27,000. Bayforest Capital Ltd bought a new stake in Pfizer during the 1st quarter worth about $28,000. North Capital Inc. bought a new stake in Pfizer during the 1st quarter worth about $28,000. WPG Advisers LLC bought a new stake in Pfizer during the 1st quarter worth about $35,000. Finally, Horizon Financial Services LLC bought a new stake in Pfizer during the 1st quarter worth about $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on PFE shares. UBS Group reissued a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley dropped their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.35.

Pfizer Stock Down 1.7%

Pfizer stock opened at $24.81 on Monday. The stock has a market cap of $141.03 billion, a P/E ratio of 13.19, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.82. The company’s 50-day moving average price is $24.86 and its two-hundred day moving average price is $24.12.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.